Fuke Qianjin Capsule and quality control method therefor
US12144841B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jan 14, 2020 |
| Grant date | Nov 19, 2024 |
| Priority date | — |
| Expiry date | Jan 14, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2236/51
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses Fuke Qianjin Capsules and a quality control method therefor. The capsules are made of Radix et caulis flemingiae, Caulis mahoniae, Herba andrographis, Zanthoxylum dissitum Hemsl., Caulis spatholobi, Radix angelicae sinensis, Radix codonopsis, and Radix rosa laevigata as raw materials. Each of the Fuke Qianjin Capsules contains not less than 2.0 mg of Z-ligustilide, and a total amount of andrographolide and dehydroandrographolide is not less than 1.9 mg. A new standard for controlling quality of the Fuke Qianjin Capsules has been established through an analysis of chemical ingredients in the Fuke Qianjin Capsules. This standard adds a variety of core ingredient content to the existing pharmacopoeia standards. According to the Fuke Qianjin Capsules made in this range, the consistency of effects between different batches is more stable. Moreover, the more the types of core ingredients are limited, the more stable the consistency of the drug effect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.